| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/14/2002 | US20020032218 Substituted stilbenes as glucose uptake enhancers |
| 03/14/2002 | US20020032214 Pharmaceutical composition comprising a compound having anti-xa activity and a platelet aggregation antagonist compound |
| 03/14/2002 | US20020032201 Compositions containing alpha-2-adrenergic agonist components |
| 03/14/2002 | US20020032197 Methods and compositions for using moclobemide |
| 03/14/2002 | US20020032192 Treatment of vasodilatory headache |
| 03/14/2002 | US20020032190 Contacting host with a cephalotaxine and an antiproliferative agent such as an alkylating agent, an intercalating agent, a metal coordination complex, a nucleoside, a nucleic acid enyme or protein inhibitor to modulate cell proliferation |
| 03/14/2002 | US20020032179 Inhibiting the hyperproliferation of malignant or neoplastic cells by treating the cells with an antiproliferative amount of 1 alpha ,24(S)-dihydroxyvitamin D2 the cells being cancers of the lung, neck and head, pancreas, endometrium, bladder |
| 03/14/2002 | US20020032174 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade |
| 03/14/2002 | US20020032169 Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue |
| 03/14/2002 | US20020032156 Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders |
| 03/14/2002 | US20020032152 Anti-helicobacter vaccine complex |
| 03/14/2002 | US20020032151 Using an agent which promotes tyrosine protein dephosphorylation in the preparation of a medicament for reducing permeability of a physiological barrier such as the blood-brain barrier |
| 03/14/2002 | US20020032148 Pharmaceutical agent containing Rho kinase inhibitor |
| 03/14/2002 | US20020031819 Screening process for antibacterial agents |
| 03/14/2002 | US20020031800 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | US20020031780 Modulators of polypeptide binding activities; for use in the treatment, prevention of infections and viral disease |
| 03/14/2002 | US20020031759 Diagnosing pancreatic defect in humans; obtain organelle sample, detect preferential organelle, monitor sample for organelle defect, diagnose pancreatic defect |
| 03/14/2002 | US20020031535 Copper, copper sulfate, sodium carbonate, turpentine, ethanol, and water |
| 03/14/2002 | US20020031529 Neurotoxin therapy for diabetes |
| 03/14/2002 | US20020031517 Administering an inhibitor of GDF-8, or a related member of Transforming Growth Factor-beta superfamily of structurally-related growth factors |
| 03/14/2002 | US20020031512 Inhibiting immunological activation of keratinocytes by administering molecule that binds to CD40 but does not activate CD40-expressing keratinocytes |
| 03/14/2002 | US20020031510 Contacting B7-positive cell with first soluble ligand which recognizes and binds B7 antigen, and contacting gp39-positive cell with second soluble ligand which recognizes and binds gp39 antigen; inhibiting rejection of transplanted tissues |
| 03/14/2002 | US20020031508 Administering inducer of P-selectin activity such that hemostasis occurs |
| 03/14/2002 | US20020031505 Antitumor compositions containing taxane derivatives |
| 03/14/2002 | US20020031497 Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
| 03/14/2002 | US20020031479 Medicaments |
| 03/14/2002 | DE10043227A1 Neuartiges entwicklungsbiologisches Gen Novel biological developmental gene |
| 03/14/2002 | DE10043124A1 Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase Method for the diagnosis of neural disorders and for the treatment of primary hemostasis deficiency |
| 03/14/2002 | DE10042137A1 sgk2 und sgk3 als diagnostische und therapeutische Targets sgk2 and sgk3 as diagnostic and therapeutic targets |
| 03/14/2002 | DE10028575A1 Integrinliganden Integrin |
| 03/14/2002 | CA2423247A1 Gene markers useful for detecting skin damage in response to ultraviolet radiation |
| 03/14/2002 | CA2422204A1 Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice |
| 03/14/2002 | CA2422200A1 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure |
| 03/14/2002 | CA2422114A1 Novel human cancer/testis antigen and gene thereof |
| 03/14/2002 | CA2421922A1 Proteases |
| 03/14/2002 | CA2421912A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | CA2421872A1 Mechanism of mitochondrial membrane permeabilization by hiv-1 vpr, mimetics of vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of vpr with ant |
| 03/14/2002 | CA2421842A1 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 03/14/2002 | CA2421834A1 Use of carp inhibitors for the treatment of heart diseases |
| 03/14/2002 | CA2421760A1 G-csf analog compositions and methods |
| 03/14/2002 | CA2421757A1 G-csf analog compositions and methods |
| 03/14/2002 | CA2421502A1 A method for treating allergies |
| 03/14/2002 | CA2421445A1 Hla binding peptides and their uses |
| 03/14/2002 | CA2421380A1 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | CA2421324A1 Mutant non-human mammal for expressing the alpha6 acetylcholine nicotinic receptor subunit and use for screening substances capable of interacting with said receptor |
| 03/14/2002 | CA2421271A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | CA2421218A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | CA2421200A1 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | CA2421197A1 Generation of combinatorial libraries and assessment thereof by deconvolution |
| 03/14/2002 | CA2421195A1 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | CA2421191A1 Methods and compositions for in vitro targeting |
| 03/14/2002 | CA2421155A1 Osteoclast-associated receptor |
| 03/14/2002 | CA2421075A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | CA2421070A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 03/14/2002 | CA2421041A1 Caveolin peptides and their use as therapeutics |
| 03/14/2002 | CA2421027A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/14/2002 | CA2420703A1 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
| 03/14/2002 | CA2419983A1 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure |
| 03/14/2002 | CA2419653A1 Prevention of acute sinusitis and sinus attack |
| 03/14/2002 | CA2419590A1 Exemestane as chemopreventing agent |
| 03/14/2002 | CA2419456A1 Methods and compositions for producing a neurosalutary effect in a subject |
| 03/14/2002 | CA2416336A1 Multivalent neuraminidase inhibitor conjugates |
| 03/14/2002 | CA2389602A1 Methods and compositions for potentiating cancer chemotherapeutic agents |
| 03/13/2002 | EP1186672A2 Polymorphisms in the human organic anion transporter C (OATP-C) gene |
| 03/13/2002 | EP1186661A1 Identification of the major capacitative calcium channel in antigen presenting cells and uses thereof |
| 03/13/2002 | EP1186318A2 Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist |
| 03/13/2002 | EP1186304A2 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| 03/13/2002 | EP1186303A2 Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| 03/13/2002 | EP1186293A2 Intermittent administration of a growth hormone secretagogue |
| 03/13/2002 | EP1185864A1 Protein localization assays for toxicity and antidotes thereto |
| 03/13/2002 | EP1185862A2 Method and compositions relating to insulin resistance disorders |
| 03/13/2002 | EP1185712A1 New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| 03/13/2002 | EP1185700A1 49 human secreted proteins |
| 03/13/2002 | EP1185673A2 Novel calpains and their use |
| 03/13/2002 | EP1185666A1 Hyaluronidase from the hirudinaria manillensis, isolation, purification and recombinant method of production |
| 03/13/2002 | EP1185649A2 The myostatin gene promoter and inhibition of activation thereof |
| 03/13/2002 | EP1185648A2 Methods and compositions for inhibiting neoplastic cell growth |
| 03/13/2002 | EP1185646A1 Recombinant nematode nicotinic receptor and uses |
| 03/13/2002 | EP1185642A2 Compositions and methods for the treatment of tumor |
| 03/13/2002 | EP1185632A1 Caspase-8 crystals, models and methods |
| 03/13/2002 | EP1185559A2 Compositions and methods for cancer treatment by selectively inhibiting vegf |
| 03/13/2002 | EP1185558A1 Peptide having preptin functionality |
| 03/13/2002 | EP1185549A2 Dna encoding a human subunit of the 5-ht3 serotonin receptor |
| 03/13/2002 | EP1185545A1 Cd4-independent hiv envelope proteins as vaccines and therapeutics |
| 03/13/2002 | EP1185316A1 Devices and compounds for treating arterial restenosis |
| 03/13/2002 | EP1185302A2 Specifically targeted catalytic antagonists and uses thereof |
| 03/13/2002 | EP1185296A2 Prevention and treatment of amyloidogenic disease |
| 03/13/2002 | EP1185295A2 Adenosine diphosphatase and activators thereof and their medical uses |
| 03/13/2002 | EP1185294A2 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 03/13/2002 | EP1185285A1 49 human secreted proteins |
| 03/13/2002 | EP1185284A1 47 human secreted proteins |
| 03/13/2002 | EP1185274A1 Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4 |
| 03/13/2002 | EP1185263A2 Receptor agonists and antagonists |
| 03/13/2002 | EP1185257A2 Treatment of acne using lipoic acid |
| 03/13/2002 | EP1185255A2 Neuroprotective and retinoprotective ophthalmologic medicines |
| 03/13/2002 | EP1185252A1 Novel formulations comprising lipid-regulating agents |
| 03/13/2002 | EP1185249A2 Methods and compositions for treating solid tumors |
| 03/13/2002 | EP1185247A1 Anti-inflammatory bioactive glass particulates |
| 03/13/2002 | EP1185246A1 Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water |
| 03/13/2002 | EP1185169A2 USE OF TRANSGENIC MICE LACKING JunB EXPRESSION IN THE MYELOID LINEAGE |